[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Organ Transplant Diagnostics Market - A Global and Regional Analysis: Focus on Offering, Transplant, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031

October 2021 | 228 pages | ID: OBC038CC05DAEN
BIS Research Inc.

US$ 5,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Market Report Coverage - Organ Transplant Diagnostics

Market Segmentation
  • Offering - Products (Kits and Assays and Consumables) and Services
  • Transplant - Solid Organ Transplant and Stem Cell Transplant
  • Application - Diagnostics (Donor Testing and Recipient Testing) and Translational Research
  • Technology - Molecular Technologies, Serology, Flow Cytometry, and Other Technologies
  • End User - Hospitals and Transplant Centers, Academic and Research Institutions, Reference Laboratories, and Other End Users
  • Regional Segmentation
  • North America – U.S., and Canada
  • Europe – Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
  • Asia-Pacific – China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
  • Latin America – Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World
  • Market Growth Drivers
  • Rising Number of Organ Transplant Procedure
  • Strategic Initiatives by Key Market Players
  • Favorable Regulatory Scenario
  • Market Challenges
  • High Cost of Organ Transplant Procedure and Diagnostics
  • Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants
  • Market Opportunities
  • Technological Advancement in Transplant Diagnostics
  • Increasing Awareness Regarding Transplants in High potential Market
  • Key Companies Profiled

    Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, bioMйrieux S.A., CareDx, Inc., ARUP Laboratories, Abbott Laboratories, Quest Diagnostics Incorporated, Eurofins Scientific, Illumina, Inc., OPKO Health, Novacyt Group, Immucor, Inc.

    Key Questions Answered in this Report:
  • How is organ transplant diagnostics revolutionizing the field of transplant care?
  • What are the major market drivers, challenges, and opportunities in the global organ transplant diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global organ transplant diagnostics market?
  • How did the COVID-19 pandemic impact the global organ transplant diagnostics ecosystem?
  • What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of organ transplant diagnostics?
  • What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Offering (products and services)
    • Transplant (solid organ transplant and stem cell transplant)
    • Application (diagnostics and translation research)
    • Technology (molecular technologies, serology, flow cytometry and other technologies)
    • End User (hospitals and transplant centers, academic and research institutions, and reference laboratories)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the organ transplant diagnostics companies in the region of their operation?
  • Who are the leading players with significant offerings in the global organ transplant diagnostics market?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • Market Overview

    Our healthcare experts have found the organ transplant diagnostics industry to be one of the most rapidly evolving and dynamic markets, and the global market for organ transplant diagnostics is predicted to grow at a CAGR of 10.92% over the forecast period of 2021-2031. The market is driven by certain factors, which include rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios.

    Currently, the organ transplant diagnostics industry is witnessing an upsurge due to the rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios are some of the critical factors which are expected to bolster the market growth.

    Furthermore, biotechnology companies are focusing on the development of robust organ transplant diagnostics solutions for applications, including diagnostics and translational research, further supporting transplant physicians and researchers to unravel insights pertaining to the intricacies present in the field of transplant care. The development of organ transplant diagnostic products and services enabled transplant physicians to establish effective strategies for organ donor screening and recipient surveillance, further offering value-based care.

    Within the research report, the market is segmented on the basis of offering, transplant, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

    Competitive Landscape

    The exponential rise in the number of organ transplant procedures worldwide has created a buzz among the biotechnology companies to further invest in the development of innovative organ transplant diagnostic tools, further aiding transplant physicians to offer value-based clinical outcomes to transplant patients. Due to the expansive product portfolio and massive geographical presence, Thermo Fisher Scientific Inc. has been the leading player in the organ transplant diagnostics ecosystem.

    On the basis of region, North America holds the largest share of the organ transplant diagnostics market due to the presence of well-established guidelines regarding transplant diagnostics, presence of legacy companies undertaking key business strategies, rising number of organ transplants, and increasing adoption of products based on advanced molecular technologies by the transplant physicians, among others. Further, increasing focus on research pertaining to the discovery of novel transplant-associated biomarkers is also expected to support the growth of the North America organ transplant diagnostics market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031.
    1 MARKETS

    1.1 Product Definition
      1.1.1 Inclusion and Exclusion
    1.2 Market Scope
      1.2.1 Scope of the Study
      1.2.2 Key Questions Answered in the Report
    1.3 Market Overview
      1.3.1 Market Definition
      1.3.2 Emerging Applications of Organ Transplant Diagnostics
      1.3.3 Market Footprint and Growth Potential, $Million, 2020-2031
      1.3.4 COVID-19 Impact on the Global Organ Transplant Diagnostics Market

    2 INDUSTRY INSIGHTS

    2.1 Overview
    2.2 Legal Requirements and Framework in the U.S.
      2.2.1 FDA Regulation
      2.2.2 CMS Regulation
    2.3 Legal Requirements and Frameworks in Europe
    2.4 Legal Requirements and Frameworks in Asia-Pacific
      2.4.1 China
      2.4.2 Japan
    2.5 Reimbursement Analysis

    3 MARKET DYNAMICS

    3.1 Overview
    3.2 Impact Analysis
    3.3 Market Drivers
      3.3.1 Rising Number of Organ Transplant Procedure
      3.3.2 Strategic Initiatives by Key Market Players
      3.3.3 Favorable Regulatory Scenario
    3.4 Market Restraints
      3.4.1 High Cost of Organ Transplant Procedure and Diagnostics
      3.4.2 Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants
    3.5 Market Opportunities
      3.5.1 Technological Advancement in Transplant Diagnostics
        3.5.1.1 Emergence of Nucleic Acid Amplification Testing (NAAT)
        3.5.1.2 Growing Focus on Molecular HLA Typing
      3.5.2 Increasing Awareness Regarding Transplants in High potential Market

    4 COMPETITIVE LANDSCAPE

    4.1 Overview
    4.2 Synergistic Activities
    4.3 Product Launches
    4.4 Product Approvals
    4.5 Mergers and Acquisitions
    4.6 Other Business Activities
    4.7 Market Share Analysis, 2019-2020
    4.8 Growth Share Analysis (Company)

    5 OFFERING, $MILLION, 2020-2031

    5.1 Overview
    5.2 Products
      5.2.1 Kits and Assays
      5.2.2 Consumables
    5.3 Services

    6 TRANSPLANT, $MILLION, 2020-2031

    6.1 Overview
    6.2 Solid Organ Transplant
      6.2.1 Kidney
      6.2.2 Liver
      6.2.3 Heart
      6.2.4 Lung
      6.2.5 Pancreas
      6.2.6 Kidney-Pancreas
      6.2.7 Other Solid Organs
    6.3 Stem Cell Transplant

    7 APPLICATION, $MILLION, 2020-2031

    7.1 Overview
    7.2 Diagnostics
      7.2.1 Donor Testing
        7.2.1.1 Infectious Disease
          7.2.1.1.1 Viral
          7.2.1.1.2 Bacterial
          7.2.1.1.3 Fungal
          7.2.1.1.4 Parasitic
        7.2.1.2 Human Leukocyte Antigen (HLA) Typing
        7.2.1.3 ABO Grouping
      7.2.2 Recipient Testing
        7.2.2.1 Infectious Disease
          7.2.2.1.1 Viral
          7.2.2.1.2 Bacterial
          7.2.2.1.3 Fungal
          7.2.2.1.4 Parasitic
        7.2.2.2 Human Leukocyte Antigen (HLA) Typing
        7.2.2.3 ABO Grouping
        7.2.2.4 Chimerism Testing
        7.2.2.5 Graft versus Host Disease (GvHD)
    7.3 Translational Research

    8 TECHNOLOGY, $MILLION, 2020-2031

    8.1 Overview
    8.2 Molecular Technologies
      8.2.1 Polymerase Chain Reaction (PCR)
        8.2.1.1 Real-Time PCR (RT-PCR)
        8.2.1.2 Digital PCR (dPCR)
      8.2.2 Sequencing
        8.2.2.1 Next-Generation Sequencing (NGS)
        8.2.2.2 Sanger Sequencing
        8.2.2.3 Other Molecular Technologies
    8.3 Serology
    8.4 Flow Cytometry (FCM)
    8.5 Other Technologies

    9 END-USER, $MILLION, 2020-2031

    9.1 Overview
    9.2 Hospitals and Transplant Centers
    9.3 Academic and Research Institutions
    9.4 Reference Laboratories
    9.5 Other End Users

    10 REGIONS, $MILLION, 2020-2031

    10.1 Overview
    10.2 North America
      10.2.1 U.S.
      10.2.2 Canada
    10.3 Europe
      10.3.1 Germany
      10.3.2 France
      10.3.3 U.K.
      10.3.4 Italy
      10.3.5 Spain
      10.3.6 Switzerland
      10.3.7 Rest-of-Europe
    10.4 Asia-Pacific
      10.4.1 China
      10.4.2 India
      10.4.3 Japan
      10.4.4 South Korea
      10.4.5 Australia
      10.4.6 Singapore
      10.4.7 Rest-of-Asia-Pacific (RoAPAC)
    10.5 Latin America
      10.5.1 Brazil
      10.5.2 Mexico
      10.5.3 Rest-of-Latin America (RoLA)
    10.6 Rest-of-the-World

    11 COMPANY PROFILES

    11.1 Overview
    11.2 Thermo Fisher Scientific Inc.
      11.2.1 Company Overview
      11.2.2 Role of Thermo Fisher Scientific Inc. in the Global Organ Transplant Diagnostics Market
      11.2.3 Financials
      11.2.3 Key Insights About Financial Health of the Company
      11.2.4 SWOT Analysis
    11.3 QIAGEN N.V.
      11.3.2 Company Overview
      11.3.3 Role of QIAGEN N.V. in the Global Organ Transplant Diagnostics Market
      11.3.4 Financials
      11.3.5 Key Insights About Financial Health of the Company
      11.3.6 SWOT Analysis
    11.4 F. Hoffmann-La Roche Ltd.
      11.4.2 Company Overview
      11.4.3 Role of F. Hoffmann-La Roche Ltd in the Global Organ Transplant Diagnostics Market
      11.4.4 Financials
      11.4.5 Key Insights About Financial Health of the Company
      11.4.6 SWOT Analysis
    11.5 Bio-Rad Laboratories, Inc.
      11.5.2 Company Overview
      11.5.3 Role of Bio-Rad Laboratories, Inc. in the Global Organ Transplant Diagnostics Market
      11.5.4 Financials
      11.5.5 Key Insights About Financial Health of the Company
      11.5.6 SWOT Analysis
    11.6 Laboratory Corporation of America Holdings
      11.6.2 Company Overview
      11.6.3 Role of Laboratory Corporation of America Holdings in the Global Organ Transplant Diagnostics Market
      11.6.4 Financials
      11.6.5 SWOT Analysis
    11.7 bioMйrieux S.A.
      11.7.2 Company Overview
      11.7.3 Role of bioMйrieux S.A. in the Global Organ Transplant Diagnostics Market
      11.7.4 Financials
      11.7.5 Key Insights About Financial Health of the Company
      11.7.6 SWOT Analysis
    11.8 CareDx, Inc.
      11.8.2 Company Overview
      11.8.3 Role of CareDx, Inc. in the Global Organ Transplant Diagnostics Market
      11.8.4 Financials
      11.8.5 Key Insights About Financial Health of the Company
      11.8.6 SWOT Analysis
    11.9 ARUP Laboratories
      11.9.2 Company Overview
      11.9.3 Role of ARUP Laboratories in the Global Organ Transplant Diagnostics Market
      11.9.4 SWOT Analysis
    11.1 Abbott Laboratories
      11.10.2 Company Overview
      11.10.3 Role of Abbott Laboratories in the Global Organ Transplant Market
      11.10.4 Financials
      11.10.5 Key Insights About Financial Health of the Company
      11.10.6 SWOT Analysis
    11.11 Quest Diagnostics Incorporated
      11.11.2 Company Overview
      11.11.3 Role of Quest Diagnostics Incorporated in the Global Organ Transplant Diagnostics Market
      11.11.4 Financials
      11.11.5 SWOT Analysis
    11.12 Eurofins Scientific
      11.12.2 Company Overview
      11.12.3 Role of Eurofins Scientific in the Global Organ Transplant Diagnostics Market
      11.12.4 Financials
      11.12.5 SWOT Analysis
    11.13 Illumina, Inc.
      11.13.2 Company Overview
      11.13.3 Role of Illumina, Inc. in the Global Organ Transplant Diagnostics Market
      11.13.4 Financials
      11.13.5 Key Insights About Financial Health of the Company
      11.13.6 SWOT Analysis
    11.14 OPKO Health
      11.14.2 Company Overview
      11.14.3 Role of OPKO Health in the Global Organ Transplant Diagnostics Market
      11.14.4 Financials
      11.14.5 Key Insights About Financial Health of the Company
      11.14.6 SWOT Analysis
    11.15 Novacyt Group
      11.15.2 Company Overview
      11.15.3 Role of Novacyt Group in the Global Organ Transplant Diagnostics Market
      11.15.4 Financials
      11.15.5 Key Insights About Financial Health of the Company
      11.15.6 SWOT Analysis
    11.16 Immucor, Inc,
      11.16.2 Company Overview
      11.16.3 Role of Immucor, Inc. in the Global Organ Transplant Diagnostics Market
      11.16.4 SWOT Analysis

    LIST OF FIGURES

    Figure 1: Figure: U.S. Solid Organ and Bone Marrow Transplant Procedures (2017-2020)
    Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Organ Transplant Diagnostics Market
    Figure 3: Global Organ Transplant Diagnostics Market (by Offering), $Million, 2020 and 2031
    Figure 4: Global Organ Transplant Diagnostics Market (by Transplant), $Million, 2020 and 2031
    Figure 5: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020 and 2031
    Figure 6: Global Organ Transplant Diagnostics Market (by Technology), $Million, 2020 and 2031
    Figure 7: Global Organ Transplant Diagnostics Market (by End Users), $Million, 2020 and 2031
    Figure 8: Global Organ Transplant Diagnostics Market Snapshot
    Figure 9: Global Organ Transplant Diagnostics Market: Research Methodology
    Figure 10: Primary Research Methodology
    Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
    Figure 12: Top-Down Approach (Segment-Wise Analysis)
    Figure 13: Global Organ Transplant Diagnostics Market Segmentation
    Figure 14: Global Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 15: Global Organ Transplant Diagnostics Market: COVID-19 Impact Analysis
    Figure 16: U.S. Solid Organ and Hematopoietic Stem Cell Transplant Data (2017-2020)
    Figure 17: Share of Key Developments and Strategies, January 2018-September 2021
    Figure 18: Share of Synergistic Activities (by Company), January 2018-September 2021
    Figure 19: Number of Product Launches (by Company), January 2018-September 2021
    Figure 20: Share of Product Approvals (by Company), January 2018-September 2021
    Figure 21: Share of Mergers and Acquisitions (by Company), January 2018–September 2021
    Figure 22: Share of Other Business Activities (by Company), January 2018- September 2021
    Figure 23: Market Share Analysis for Global Organ Transplant Diagnostics Market, $Million, 2019 and 2020
    Figure 24: Growth Share Analysis for Global Organ Transplant Diagnostics Market (by Company), 2020
    Figure 25: Figure 8.1: Global Organ Transplant Diagnostics Market (by Offering)
    Figure 26: Global Organ Transplant Diagnostics Market (by Offering), 2020 and 2031
    Figure 27: Global Organ Transplant Diagnostics Market (by Product), $Million, 2020-2031
    Figure 28: Global Organ Transplant Diagnostics Market (Kits and Assays), 2020-2031
    Figure 29: Global Organ Transplant Diagnostics Market (Consumables), $Million, 2020-2031
    Figure 30: Global Organ Transplant Diagnostics Market (Services), $Million, 2020-2031
    Figure 31: Global Organ Transplant Diagnostics Market (Transplant)
    Figure 32: Global Organ Transplant Diagnostics Market (Transplant), 2020 and 2031
    Figure 33: Global Organ Transplant Diagnostics Market (by Solid Organ Transplants), $Million, 2020-2031
    Figure 34: Global Organ Transplant Diagnostics Market (by Solid Organ Transplant), 2020 and 2031
    Figure 35: Global Organ Transplant Diagnostics Market (Kidney, by Solid Organ Transplants), $Million, 2020-2031
    Figure 36: Global Organ Transplant Diagnostics Market (Liver, by Solid Organ Transplants), $Million, 2020-2031
    Figure 37: Global Organ Transplant Diagnostics Market (Heart, by Solid Organ Transplants), $Million, 2020-2031
    Figure 38: Global Organ Transplant Diagnostics Market (Lung, by Solid Organ Transplants), $Million, 2020-2031
    Figure 39: Global Organ Transplant Diagnostics Market (Pancreas, by Solid Organ Transplants), $Million, 2020-2031
    Figure 40: Global Organ Transplant Diagnostics Market (Kidney-Pancreas, by Solid Organ Transplants), $Million, 2020-2031
    Figure 41: Global Organ Transplant Diagnostics Market (Other Solid Organs, by Solid Organs), $Million, 2020-2031
    Figure 42: Global Organ Transplant Diagnostics Market (Stem Cell Transplant), $Million, 2020-2031
    Figure 43: Global Organ Transplant Diagnostics Market (by Application)
    Figure 44: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020-2031
    Figure 45: Global Organ Transplant Diagnostics Market (Diagnostics), $Million, 2020-2031
    Figure 46: Global Organ Transplant Diagnostics Market (by Diagnostics), 2020 and 2031
    Figure 47: Global Organ Transplant Diagnostics Market (Donor Testing), $Million, 2020-2031
    Figure 48: Global Organ Transplant Diagnostics Market (by Donor Testing), 2020 and 2031
    Figure 49: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), $Million, 2020-2031
    Figure 50: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), 2020 and 2031
    Figure 51: Global Organ Transplant Diagnostics Market (Viral, by Donor Testing), $Million, 2020-2031
    Figure 52: Global Organ Transplant Diagnostics Market (Bacterial, by Donor Testing), $Million, 2020-2031
    Figure 53: Global Organ Transplant Diagnostics Market (Fungal, by Donor Testing), $Million, 2020-2031
    Figure 54: Global Organ Transplant Diagnostics Market (Parasitic, by Donor Testing), $Million, 2020-2031
    Figure 55: Global Organ Transplant Diagnostics Market (HLA Typing, by Donor Testing), $Million, 2020-2031
    Figure 56: Global Organ Transplant Diagnostics Market (ABO Grouping, by Donor Testing), $Million, 2020-2031
    Figure 57: Global Organ Transplant Diagnostics Market (Recipient Testing), $Million, 2020-2031
    Figure 58: Global Organ Transplant Diagnostics Market (by Recipient Testing), 2020 and 2031
    Figure 59: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), $Million, 2020-2031
    Figure 60: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), 2020 and 2031
    Figure 61: Global Organ Transplant Diagnostics Market (Viral, by Recipient Testing), $Million, 2020-2031
    Figure 62: Global Organ Transplant Diagnostics Market (Bacterial, by Recipient Testing), $Million, 2020-2031
    Figure 63: Global Organ Transplant Diagnostics Market (Fungal, by Recipient Testing), $Million, 2020-2031
    Figure 64: Global Organ Transplant Diagnostics Market (Parasitic, by Recipient Testing), $Million, 2020-2031
    Figure 65: Global Organ Transplant Diagnostics Market (HLA Typing, by Recipient Testing), $Million, 2020-2031
    Figure 66: Global Organ Transplant Diagnostics Market (ABO Grouping, by Recipient Testing), $Million, 2020-2031
    Figure 67: Global Organ Transplant Diagnostics Market (Chimerism Testing, by Recipient Testing), $Million, 2020-2031
    Figure 68: Global Organ Transplant Diagnostics Market (GvHD, by Recipient Testing), $Million, 2020-2031
    Figure 69: Global Organ Transplant Diagnostics Market (Translational Research), $Million, 2020 – 2031
    Figure 70: Global Organ Transplant Diagnostics Market (by Technology)
    Figure 71: Global Organ Transplant Diagnostics Market (by Technology), 2020 and 2021
    Figure 72: Global Organ Transplant Diagnostics Market (Molecular Technologies), $Million, 2020-2021
    Figure 73: Global Organ Transplant Diagnostics Market (by Molecular Technologies), 2020 and 2031
    Figure 74: Global Organ Transplant Diagnostics Market (PCR), $Million, 2021-2031
    Figure 75: Global Organ Transplant Diagnostics Market (by PCR), 2020 and 2031
    Figure 76: Global Organ Transplant Diagnostics Market (RT-PCR, by PCR), $Million, 2020 and 2031
    Figure 77: Global Organ Transplant Diagnostics Market (dPCR, by PCR), $Million, 2020 and 2031
    Figure 78: Global Organ Transplant Diagnostics Market (Sequencing), $Million, 2020-2031
    Figure 79: Global Organ Transplant Diagnostics Market (by Sequencing), 2020 and 2031
    Figure 80: Global Organ Transplant Diagnostics Market (NGS, by Sequencing), $Million, 2020-2031
    Figure 81: Global Organ Transplant Diagnostics Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
    Figure 82: Global Organ Transplant Diagnostics Market (Other Molecular Technologies), $Million, 2020-2031
    Figure 83: Global Organ Transplant Diagnostics Market (Serology), $Million, 2020-2031
    Figure 84: Global Organ Transplant Diagnostics Market (Flow Cytometry), $Million, 2020-2031
    Figure 85: Global Organ Transplant Diagnostics Market (Other Technologies), $Million, 2020-2031
    Figure 86: Global Organ Transplant Diagnostics Market (by End User)
    Figure 87: Global Organ Transplant Diagnostics Market (by End User), $Million, 2020 and 2031
    Figure 88: Global Organ Transplant Diagnostics Market (Hospitals and Transplant Centres), $Million, 2020-2031
    Figure 89: Global Organ Transplant Diagnostics Market (Academic and Research Institutions), $Million, 2020-2031
    Figure 90: Global Organ Transplant Diagnostics Market (Reference Laboratories), $Million, 2020-2031
    Figure 91: Global Organ Transplant Diagnostics Market (Other End Users), $Million, 2020-2031
    Figure 92: Global Organ Transplant Diagnostics Market (by Region): Market Snapshot
    Figure 93: Global Organ Transplant Diagnostics Market (by Region), $Million, 2020-2031
    Figure 94: Global Organ Transplant Diagnostics Market (by Region), 2020 and 2031
    Figure 95: North America Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 96: North America: Market Dynamics
    Figure 97: North America Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
    Figure 98: U.S. Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 99: Canada Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 100: Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 101: Europe: Market Dynamics
    Figure 102: Europe Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
    Figure 103: Germany Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 104: France Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 105: U.K. Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 106: Italy Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 107: Spain Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 108: Switzerland Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 109: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 110: Asia-Pacific Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 111: APAC: Market Dynamics
    Figure 112: APAC Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
    Figure 113: China Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 114: India Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 115: Japan Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 116: South Korea Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 117: Australia Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 118: Singapore Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 119: RoAPAC Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 120: Latin America Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 121: Latin America: Market Dynamics
    Figure 122: Global Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
    Figure 123: Brazil Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 124: Mexico Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 125: RoLA Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 126: RoW Organ Transplant Diagnostics Market, $Million, 2020-2031
    Figure 127: Total Number of Companies Profiled
    Figure 128: Thermo Fisher Scientific Inc.: Product Portfolio
    Figure 129: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
    Figure 130: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
    Figure 131: : Thermo Fisher Scientific Inc.: Revenue (by region), 2018-2020
    Figure 132: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
    Figure 133: : Thermo Fisher Scientific Inc: SWOT Analysis
    Figure 134: QIAGEN N.V.: Product Portfolio
    Figure 135: QIAGEN N.V.: Overall Financials, 2018-2020
    Figure 136: QIAGEN N.V.: Revenue (by Segment), 2018-2020
    Figure 137: QIAGEN N.V.: Revenue (by Region), 2018-2020
    Figure 138: QIAGEN N.V.: R&D Expenditure, 2018-2020
    Figure 139: QIAGEN N.V.: SWOT Analysis
    Figure 140: F. Hoffmann-La Roche Ltd: Product Portfolio
    Figure 141: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
    Figure 142: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
    Figure 143: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
    Figure 144: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
    Figure 145: F. Hoffmann-La Roche Ltd: SWOT Analysis
    Figure 146: Bio-Rad Laboratories, Inc.: Product Portfolio
    Figure 147: : Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
    Figure 148: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
    Figure 149: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
    Figure 150: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
    Figure 151: Bio-Rad Laboratories, Inc.: SWOT Analysis
    Figure 152: Laboratory Corporation of America Holdings: Service Portfolio
    Figure 153: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
    Figure 154: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
    Figure 155: Laboratory Corporation of America Holdings: SWOT Analysis
    Figure 156: bioMйrieux S.A: Product Portfolio
    Figure 157: bioMйrieux S.A.: Overall Financials, 2018-2020
    Figure 158: bioMйrieux S.A.: Revenue (by Segment), 2018-2020
    Figure 159: bioMйrieux S.A.: Revenue (by Region), 2018-2020
    Figure 160: bioMйrieux S.A.: R&D Expenditure, 2018-2020
    Figure 161: bioMйrieux S.A.: SWOT Analysis
    Figure 162: CareDx Inc.: Product Portfolio
    Figure 163: CareDx, Inc.: Overall Financials, 2018-2020
    Figure 164: CareDx, Inc.: Revenue (by Segment), 2018-2020
    Figure 165: CareDx, Inc.: Revenue (by Region), 2018-2020
    Figure 166: CareDx, Inc.: R&D Expenditure, 2018-2020
    Figure 167: CareDx, Inc., SWOT Analysis
    Figure 168: ARUP Laboratories: Product Portfolio
    Figure 169: ARUP Laboratories: SWOT Analysis
    Figure 170: Abbott Laboratories: Product Portfolio
    Figure 171: Abbott laboratories: Overall Financials, 2018-2020
    Figure 172: Abbott Laboratories.: Revenue (by Segment), 2018-2020
    Figure 173: Abbott Laboratories: Revenue (by Region), 2018-2020
    Figure 174: Abbott Laboratories: R&D Expenditure, 2018-2020
    Figure 175: Abbott Laboratories: SWOT Analysis
    Figure 176: Quest Diagnostics Incorporated: Product Portfolio
    Figure 177: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
    Figure 178: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
    Figure 179: Quest Diagnostics Incorporated: SWOT Analysis
    Figure 180: Eurofins Scientific: Service Portfolio
    Figure 181: Eurofins Scientific: Overall Financials, 2018-2020
    Figure 182: Eurofins Scientific: Revenue (by Region), 2018-2020
    Figure 183: Eurofins Scientific: SWOT Analysis
    Figure 184: Illumina Inc, Product Portfolio
    Figure 185: Illumina, Inc, Overall Financials, 2018-2020
    Figure 186: Illumina, Inc. Revenue (by Segment), 2018-2020
    Figure 187: Illumina, Inc.: Revenue (by Region), 2018-2020
    Figure 188: Illumina, Inc: R&D Expenditure, 2018-2020
    Figure 189: Illumina, Inc: SWOT Analysis
    Figure 190: OPKO Health: Product Portfolio
    Figure 191: OPKO Health: Overall Financials, 2018-2020
    Figure 192: OPKO Health: Revenue (by Region), 2018-2020
    Figure 193: OPKO Health: R&D Expenditure, 2018-2020
    Figure 194: OPKO Health: SWOT Analysis
    Figure 195: Novacyt Group: Product Portfolio
    Figure 196: Novacyt Group: Overall Financials, 2018-2020
    Figure 197: Novacyt Group.: Revenue (by Segment): 2018-2020
    Figure 198: Novacyt Group: R&D Expenditure, 2018-2020
    Figure 199: Novacyt Group: SWOT Analysis
    Figure 200: Immucor, Inc: Product Portfolio
    Figure 201: Immucor, Inc.: SWOT Analysis

    LIST OF TABLES

    Table 1: Key Coverage Providers for Organ Transplant Diagnostics Tests
    Table 2: Likert Scale
    Table 3: Impact Analysis of Market Drivers
    Table 4: Impact Analysis of Market Restraints
    Table 5: Companies Providing Kits and Assays:
    Table 6: Companies Offering Consumables:
    Table 7: Table: Companies Offering Consumables:
    Table 8: RT-PCR-Based Organ Transplant Diagnostic Products
    Table 9: dPCR-Based Organ Transplant Diagnostic Products
    Table 10: NGS-Based Organ Transplant Diagnostic Products
    Table 11: Sanger Sequencing-Based Organ Transplant Diagnostic Products
    Table 12: Other Technologies-Based Organ Transplant Diagnostic Products
    Table 13: Serology-Based Organ Transplant Diagnostic Products
    Table 14: FCM-Based Organ Transplant Diagnostic Products


    More Publications